Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention
Chuanhao Xiong,Jingzhu Wu,Yuhang Ma,Na Li,Xuejiao Wang,Yao Li,Xiaoying Ding
DOI: https://doi.org/10.2147/dmso.s451129
2024-02-21
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Chuanhao Xiong, 1, &ast Jingzhu Wu, 1, &ast Yuhang Ma, 1, &ast Na Li, 1 Xuejiao Wang, 1 Yao Li, 2 Xiaoying Ding 1 1 Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; 2 Department of Laboratory Animal Science, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaoying Ding, Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Hongkou District, Shanghai, 200080, People's Republic of China, Email Yao Li, Department of Laboratory Animal Science, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, People's Republic of China, Email Purpose: Polycystic ovary syndrome (PCOS) is a frequent cause of infertility in reproductive-age women. Our work aims to evaluate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on gut microbiota, with metabolic parameters including body weight and the hormone profile in PCOS. Patients and Methods: Dehydroepiandrosterone (DHEA)-induced PCOS mice were established and then treated with two GLP-1RAs: liraglutide and novel form semaglutide for four weeks. Changes in body weight and metabolic parameters were measured. Fecal samples were collected and analyzed using metagenomic sequencing. Results: Liraglutide and semaglutide modulated both alpha and beta diversity of the gut microbiota in PCOS. Liraglutide increased the Bacillota-to-Bacteroidota ratio through up-regulating the abundance of butyrate-producing members of Bacillota like Lachnospiraceae. Moreover, liraglutide showed the ability to reverse the altered microbial composition and the disrupted microbiota functions caused by PCOS. Semaglutide increased the abundance of Helicobacter in PCOS mice (p < 0.01) which was the only bacteria found negatively correlated with body weight. Moreover, pathways involving porphyrin and flavonoids were increased after semaglutide intervention. Conclusion: Liraglutide and semaglutide improved reproductive and metabolic disorders by modulating the whole structure of gut microbiota in PCOS. The greater efficacy in weight loss compared with liraglutide observed after semaglutide intervention was positively related with Helicobacter . The study may provide new ideas in the treatment and the underlying mechanisms of GLP-1RAs to improve PCOS. Keywords: PCOS, GLP-1 receptor agonists, gut microbiota, metabolism Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in reproductive-aged women, with a worldwide prevalence of up to 18%. 1 The pathophysiological mechanism of PCOS is not yet fully elucidated but might be related to abdominal obesity, insulin resistance, hyperandrogenemia, and low-grade metabolic inflammation. 2 The high prevalence as well as the heterogeneous character increases the risk of infertility, endometrial carcinoma, and cardiovascular disease (CVD), which poses a huge challenge to public health and contributes to the lack of effective clinical treatments. 3 A type of antihyperglycemic medicines collectively known as glucagon-like peptide-1 receptor agonists (GLP-1RAs) was reported to have a significant weight-sparing effect in patients with type 2 diabetes (T2D), as well as in obese or overweight individuals. 4,5 Moreover, they also showed the ability to improve hyperandrogenism and insulin resistance. 6 Due to their beneficial effects on weight loss and metabolic disorders, GLP-1RAs have been recently studied for the clinical treatment of polycystic ovary syndrome. 7 As reported, GLP-1RAs could significantly lose weight and improve insulin sensitivity and other glycemic parameters, as well as reduce the risk of CVD. 8–10 However, the underlying mechanisms of GLP-1 RAs in ameliorating PCOS still remain to be verified. Liraglutide has been one of the most applied GLP-1RAs in the clinical study of PCOS women, with a half-life of 13 hours. 11 Semaglutide, on the other hand, is a longer-acting GLP-1RA with a half-life of 168–184 hours, which was recently approved by the United States Food and Drug Administration (FDA) in 2021. 12 Our previous study found that both liraglutide and semaglutide had beneficial effects on reproductive and metabolic disturbances in DHEA-induced PCOS model mice, as well as the ability of anti-inflammation and promoting the browning of white adipose ti -Abstract Truncated-
endocrinology & metabolism